American Century Companies Inc. Has $13.62 Million Stock Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

American Century Companies Inc. lifted its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 418.

1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 862,365 shares of the company’s stock after purchasing an additional 695,932 shares during the quarter. American Century Companies Inc.



owned approximately 0.10% of Dr. Reddy’s Laboratories worth $13,617,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC boosted its position in Dr. Reddy’s Laboratories by 423.

3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after purchasing an additional 1,507 shares during the period. POM Investment Strategies LLC boosted its holdings in shares of Dr.

Reddy’s Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after buying an additional 1,820 shares during the period.

Farther Finance Advisors LLC grew its stake in Dr. Reddy’s Laboratories by 461.0% in the 4th quarter.

Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock valued at $40,000 after buying an additional 2,093 shares during the last quarter. Independence Bank of Kentucky raised its holdings in Dr. Reddy’s Laboratories by 400.

0% in the 4th quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock worth $44,000 after acquiring an additional 2,220 shares during the period. Finally, Allworth Financial LP lifted its position in Dr.

Reddy’s Laboratories by 447.8% during the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after acquiring an additional 2,230 shares during the last quarter.

Institutional investors own 3.85% of the company’s stock. Dr.

Reddy’s Laboratories Stock PerformanceNYSE:RDY opened at $13.17 on Wednesday. The firm’s 50-day moving average is $13.

42 and its 200-day moving average is $14.56. The company has a market cap of $10.

99 billion, a price-to-earnings ratio of 20.96 and a beta of 0.48.

The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.

92. Dr. Reddy’s Laboratories Limited has a 52-week low of $12.

50 and a 52-week high of $16.89. Dr.

Reddy’s Laboratories (NYSE:RDY – Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.

19 by $0.01. Dr.

Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%.

Equities research analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Analyst Ratings ChangesSeveral equities research analysts have recently issued reports on RDY shares. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

Get Our Latest Report on RDYAbout Dr. Reddy’s Laboratories (Free Report)Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.

It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.Read MoreFive stocks we like better than Dr.

Reddy’s LaboratoriesWhat Are Dividend Achievers? An IntroductionD-Wave: Multiple Use Cases Emerge Following Quantum SupremacyInsider Selling Explained: Can it Inform Your Investing Choices?Amazon Falls Back to a Key Support Line: Here’s How to Play It3 Fintech Stocks With Good 2021 ProspectsBuffett Trims Equities, But Still Keeps Buying This Stock.